Numerous studies have been performed over the last decade to exploit the complexity of genomic and transcriptomic lesions driving the initiation of acute myeloid leukemia (AML). These studies have helped improve risk classification and treatment options. Detailed molecular characterization of longitudinal AML samples is sparse, however; meanwhile, relapse and therapy resistance represent the main challenges in AML care. To this end, we performed transcriptome-wide RNA sequencing of longitudinal diagnosis, relapse, and/or primary resistant samples from 47 adult and 23 pediatric AML patients with known mutational background. Gene expression analysis revealed the association of short event-free survival with overexpression of GLI2 and IL1R1, a...
The V-domain Ig suppressor of T-cell activation (VISTA) has been recognized as a critical negative r...
Acute myeloid leukaemia (AML) is a clinically and molecularly heterogeneous disease characterised by...
BACKGROUND: Acute myeloid leukemia (AML) is a heterogeneous and aggressive blood cancer that results...
Numerous studies have been performed over the last decade to exploit the complexity of genomic and t...
Numerous studies have been performed over the last decade to exploit the complexity of genomic and t...
Numerous studies have been performed over the last decade to exploit the complexity of genomic and t...
Numerous studies have been performed over the last decade to exploit the complexity of genomic and t...
Numerous studies have been performed over the last decade to exploit the complexity of genomic and t...
The prognosis for patients suffering from acute myeloid leukemia (AML) remains unsatisfactory and su...
© 2019 Anna QuaglieriAcute myeloid leukaemia (AML) is a cancer of the blood affecting the normal dev...
The effective treatment of patients in certain subgroups of pediatric acute myeloid leukemia (AML) a...
peer reviewedBACKGROUND: Still 30-40% of pediatric acute myeloid leukemia (pedAML) patients relapse....
BACKGROUND: Still 30-40% of pediatric acute myeloid leukemia (pedAML) patients relapse. Delineation ...
Background: Acute Myeloid Leukemia (AML) is a complex and heterogeneous hematologic malignancy. Howe...
Background The majority of individuals with acute myeloid leukemia (AML) respond to initial chemothe...
The V-domain Ig suppressor of T-cell activation (VISTA) has been recognized as a critical negative r...
Acute myeloid leukaemia (AML) is a clinically and molecularly heterogeneous disease characterised by...
BACKGROUND: Acute myeloid leukemia (AML) is a heterogeneous and aggressive blood cancer that results...
Numerous studies have been performed over the last decade to exploit the complexity of genomic and t...
Numerous studies have been performed over the last decade to exploit the complexity of genomic and t...
Numerous studies have been performed over the last decade to exploit the complexity of genomic and t...
Numerous studies have been performed over the last decade to exploit the complexity of genomic and t...
Numerous studies have been performed over the last decade to exploit the complexity of genomic and t...
The prognosis for patients suffering from acute myeloid leukemia (AML) remains unsatisfactory and su...
© 2019 Anna QuaglieriAcute myeloid leukaemia (AML) is a cancer of the blood affecting the normal dev...
The effective treatment of patients in certain subgroups of pediatric acute myeloid leukemia (AML) a...
peer reviewedBACKGROUND: Still 30-40% of pediatric acute myeloid leukemia (pedAML) patients relapse....
BACKGROUND: Still 30-40% of pediatric acute myeloid leukemia (pedAML) patients relapse. Delineation ...
Background: Acute Myeloid Leukemia (AML) is a complex and heterogeneous hematologic malignancy. Howe...
Background The majority of individuals with acute myeloid leukemia (AML) respond to initial chemothe...
The V-domain Ig suppressor of T-cell activation (VISTA) has been recognized as a critical negative r...
Acute myeloid leukaemia (AML) is a clinically and molecularly heterogeneous disease characterised by...
BACKGROUND: Acute myeloid leukemia (AML) is a heterogeneous and aggressive blood cancer that results...